HomeENLV • NASDAQ
Enlivex Therapeutics Ltd
Follow
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.12M | -44.58% |
Net income | -2.60M | 56.36% |
Net profit margin | — | — |
Earnings per share | -0.12 | 62.50% |
EBITDA | -2.96M | 45.36% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 24.51M | -19.65% |
Total assets | 29.80M | -36.52% |
Total liabilities | 3.21M | -60.65% |
Total equity | 26.59M | — |
Shares outstanding | 21.99M | — |
Price to book | 0.78 | — |
Return on assets | -25.28% | — |
Return on capital | -27.48% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -2.60M | 56.36% |
Cash from operations | -2.62M | 51.88% |
Cash from investing | 1.40M | -64.59% |
Cash from financing | 250.00K | — |
Net change in cash | -970.00K | 35.07% |
Free cash flow | -1.46M | 52.50% |
Previous close
$0.95
Day range
$0.85 - $0.94
Year range
$0.81 - $4.21
Market cap
19.45M USD
Avg Volume
205.98K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
Jan 22, 2012
Website
Employees
49
